Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 409 to 414 of 414 entries
Sorted by: Best Match Show Resources per page
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.

Journal of the American Heart Association

Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, Rouleau JL, Minamisawa M, Shah AM, Lefkowitz MP, Zile MR, Van Veldhuisen DJ, Pfeffer MA, Anand IS, Maggioni AP, Senni M, Claggett BL, Solomon SD, McMurray JJV.
PMID: 34796742
J Am Heart Assoc. 2021 Dec 07;10(23):e021494. doi: 10.1161/JAHA.121.021494. Epub 2021 Nov 19.

Background Little is known about the impact of chronic obstructive pulmonary disease (COPD) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and Results We examined outcomes in patients with heart failure with preserved ejection fraction, according...

Cite
Mooney L, Hawkins NM, Jhund PS, et al. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021;10(23):e021494doi: 10.1161/JAHA.121.021494.
Mooney, L., Hawkins, N. M., Jhund, P. S., Redfield, M. M., Vaduganathan, M., Desai, A. S., Rouleau, J. L., Minamisawa, M., Shah, A. M., Lefkowitz, M. P., Zile, M. R., Van Veldhuisen, D. J., Pfeffer, M. A., Anand, I. S., Maggioni, A. P., Senni, M., Claggett, B. L., Solomon, S. D., & McMurray, J. J. V. (2021). Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. Journal of the American Heart Association, 10(23), e021494. https://doi.org/10.1161/JAHA.121.021494
Mooney, Leanne, et al. "Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF." Journal of the American Heart Association vol. 10,23 (2021): e021494. doi: https://doi.org/10.1161/JAHA.121.021494
Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, Rouleau JL, Minamisawa M, Shah AM, Lefkowitz MP, Zile MR, Van Veldhuisen DJ, Pfeffer MA, Anand IS, Maggioni AP, Senni M, Claggett BL, Solomon SD, McMurray JJV. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 Dec 07;10(23):e021494. doi: 10.1161/JAHA.121.021494. Epub 2021 Nov 19. PMID: 34796742.
Copy Download .nbib Format: NLM
Reply.

The Journal of pediatrics

Inder TE, de Vries LS, Ment LR.
PMID: 34390695
J Pediatr. 2021 Dec;239:248-249. doi: 10.1016/j.jpeds.2021.08.007. Epub 2021 Aug 11.

No abstract available.

Cite
Inder TE, de Vries LS, Ment LR. Reply. J Pediatr. 2021;239:248-249doi: 10.1016/j.jpeds.2021.08.007.
Inder, T. E., de Vries, L. S., & Ment, L. R. (2021). Reply. The Journal of pediatrics, 239248-249. https://doi.org/10.1016/j.jpeds.2021.08.007
Inder, Terrie E, et al. "Reply." The Journal of pediatrics vol. 239 (2021): 248-249. doi: https://doi.org/10.1016/j.jpeds.2021.08.007
Inder TE, de Vries LS, Ment LR. Reply. J Pediatr. 2021 Dec;239:248-249. doi: 10.1016/j.jpeds.2021.08.007. Epub 2021 Aug 11. PMID: 34390695.
Copy Download .nbib Format: NLM
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.

Circulation

Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV.
PMID: 33040613
Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12.

BACKGROUND: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to...

Cite
Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2020;143(4):298-309doi: 10.1161/CIRCULATIONAHA.120.050391.
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., Kitakaze, M., Merkley, B., O'Meara, E., Shou, M., Tereshchenko, S., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Bengtsson, O., Langkilde, A. M., Sjöstrand, M., & McMurray, J. J. V. (2021). Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation, 143(4), 298-309. https://doi.org/10.1161/CIRCULATIONAHA.120.050391
Jhund, Pardeep S, et al. "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF." Circulation vol. 143,4 (2021): 298-309. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050391
Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12. PMID: 33040613; PMCID: PMC7834909.
Copy Download .nbib Format: NLM
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.

BMC cancer

Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Amann A, Eisterer W, Romeder F, Piringer G, Ilhan-Mutlu A, Wöll E, Greil R, Weiss L.
PMID: 35012477
BMC Cancer. 2022 Jan 10;22(1):51. doi: 10.1186/s12885-021-09115-6.

BACKGROUND: Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing.METHODS: In this multi-institutional retrospective...

Cite
Schlintl V, Huemer F, Rinnerthaler G, et al. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC Cancer. 2022;22(1):51doi: 10.1186/s12885-021-09115-6.
Schlintl, V., Huemer, F., Rinnerthaler, G., Melchardt, T., Winder, T., Reimann, P., Riedl, J., Amann, A., Eisterer, W., Romeder, F., Piringer, G., Ilhan-Mutlu, A., Wöll, E., Greil, R., & Weiss, L. (2022). Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC cancer, 22(1), 51. https://doi.org/10.1186/s12885-021-09115-6
Schlintl, Verena, et al. "Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort." BMC cancer vol. 22,1 (2022): 51. doi: https://doi.org/10.1186/s12885-021-09115-6
Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Amann A, Eisterer W, Romeder F, Piringer G, Ilhan-Mutlu A, Wöll E, Greil R, Weiss L. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC Cancer. 2022 Jan 10;22(1):51. doi: 10.1186/s12885-021-09115-6. PMID: 35012477; PMCID: PMC8744304.
Copy Download .nbib Format: NLM
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.

Journal of the National Cancer Institute

Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q.
PMID: 34505880
J Natl Cancer Inst. 2022 Jan 11;114(1):60-67. doi: 10.1093/jnci/djab187.

BACKGROUND: Disease-free survival (DFS) with a 3-year median follow-up (3-year DFS) was validated as a surrogate for overall survival (OS) with a 5-year median follow-up (5-year OS) in adjuvant chemotherapy colon cancer (CC) trials. Recent data show further improvements...

Cite
Yin J, Salem ME, Dixon JG, et al. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022;114(1):60-67doi: 10.1093/jnci/djab187.
Yin, J., Salem, M. E., Dixon, J. G., Jin, Z., Cohen, R., DeGramont, A., Van Cutsem, E., Taieb, J., Alberts, S. R., Wolmark, N., Schmoll, H. J., Saltz, L. B., George, T. J., Goldberg, R. R. M., Kerr, R., Lonardi, S., Yoshino, T., Yothers, G., Grothey, A., Andre, T., & Shi, Q. (2022). Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 114(1), 60-67. https://doi.org/10.1093/jnci/djab187
Yin, Jun, et al. "Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials." Journal of the National Cancer Institute vol. 114,1 (2022): 60-67. doi: https://doi.org/10.1093/jnci/djab187
Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022 Jan 11;114(1):60-67. doi: 10.1093/jnci/djab187. PMID: 34505880; PMCID: PMC8755492.
Copy Download .nbib Format: NLM
Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program.

Edwards S, Althoff R, Hudziak JJ, Martin A, Stein JA, Anders T, Davison Y, Frosch E, Horst R, Hunt J, Joshi SV, Kitts RL, Larson J, Leckman J, O'Brien J, Lowenhaupt E, Pruitt D, Malloy E, Partner A, Sarles R, Sikich L, Wells L, Kolevzon A.
UIID-AD: 2895
2013;37:321-4. doi: 10.1176/appi.ap.12070136.

OBJECTIVE: There is a critical shortage of child and adolescent psychiatrists in the United States. Increased exposure, through mentorship, clinical experiences, and research opportunities, may increase the number of medical students selecting child and adolescent psychiatry (CAP) as a...

Cite
Edwards S, Althoff R, Hudziak JJ, et al. Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program. 2013;37:321-4doi: 10.1176/appi.ap.12070136.
Edwards, S., Althoff, R., Hudziak, J. J., Martin, A., Stein, J. A., Anders, T., Davison, Y., Frosch, E., Horst, R., Hunt, J., Joshi, S. V., Kitts, R. L., Larson, J., Leckman, J., O'Brien, J., Lowenhaupt, E., Pruitt, D., Malloy, E., Partner, A., Sarles, R., Sikich, L., Wells, L., & Kolevzon, A. (2013). Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program. 37321-4. https://doi.org/10.1176/appi.ap.12070136
Edwards, S, et al. "Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program." vol. 37 (2013): 321-4. doi: https://doi.org/10.1176/appi.ap.12070136
Edwards S, Althoff R, Hudziak JJ, Martin A, Stein JA, Anders T, Davison Y, Frosch E, Horst R, Hunt J, Joshi SV, Kitts RL, Larson J, Leckman J, O'Brien J, Lowenhaupt E, Pruitt D, Malloy E, Partner A, Sarles R, Sikich L, Wells L, Kolevzon A. Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program. 2013;37:321-4. doi: 10.1176/appi.ap.12070136. UIID-AD: 2895.
Copy Download .nbib Format: NLM
Showing 409 to 414 of 414 entries